Medical Device 510(k) Submission
An illustrative scenario showing how a device company can prepare a well-organized 510(k) — predicate selection, substantial-equivalence documentation, and managed FDA correspondence — to keep its review on track.
- Predicate
- Predicate selection
- SE Package
- Substantial equivalence
- FDA Q&A
- Correspondence managed
The Scenario
Consider a venture-backed medical device company developing diagnostic equipment for point-of-care testing, with a flagship portable blood analyzer aimed at the traditional laboratory testing market. The walkthrough below shows how Assurentry's 510(k) workflow applies — the company and figures are illustrative.
Illustrative Profile
- Stage:
- Series B ($28M raised)
- Device Class:
- Class II
- Pathway:
- 510(k)
- Employees:
- 45
The Challenge
In this scenario the company has completed product development and clinical testing but faces investor pressure to achieve FDA clearance quickly. An initial 510(k) attempt prepared internally receives an Additional Information (AI) request that threatens to delay clearance by 6+ months — a common outcome when a submission is incomplete.
Critical Challenges
- •FDA AI request identified 15 deficiencies in submission
- •Predicate device selection was questioned by reviewers
- •Performance testing data presentation was inadequate
- •Software documentation did not meet FDA expectations
- •Investor milestone deadline in 120 days
The Solution
We assembled a team of regulatory specialists, including a former FDA reviewer, to rescue the submission and get it back on track:
Week 1-2: Comprehensive Assessment
- Complete review of original 510(k) submission (21 CFR Part 807 Subpart E) and the FDA's Additional Information request, which cited 15 specific deficiencies
- Gap analysis of performance testing data vs. FDA expectations under the applicable recognized consensus standards
- Evaluation of predicate device strategy -- the original submission used a single predicate that FDA reviewers questioned due to significant technological differences. Our team identified two alternative predicates using FDA's 510(k) Premarket Notification Database and AccessGUDID
- Scheduled and conducted a Pre-Submission (Q-Sub) meeting with FDA under the Q-Sub program guidance to clarify acceptance criteria before revising the submission
Week 3-6: Submission Restructure
- Developed a split-predicate strategy using two cleared predicates, each covering different technological characteristics -- this approach provided a stronger substantial equivalence argument by comparing each feature to the most appropriate predicate
- Restructured performance data presentation with clear comparison tables following the FDA-recommended "side-by-side comparison" format from the 510(k) Program guidance
- Rewrote software documentation to align with FDA's "Guidance for the Content of Premarket Submissions for Device Software Functions" including software level of concern determination, hazard analysis, and verification/validation evidence
- Added missing biocompatibility testing documentation per ISO 10993-1 for patient-contacting components, including cytotoxicity, sensitization, and irritation testing reports
Week 7-8: AI Response Preparation
- Drafted comprehensive responses to all 15 deficiencies with cross-references to supporting evidence throughout the submission package
- Internal quality review by our team including a former CDRH reviewer who validated the response strategy and supporting evidence against current FDA reviewer expectations
- Final submission assembly following eCopy/eSTAR format requirements, QC check against FDA Refuse to Accept checklist, and dry-run review
- Submitted complete AI response package electronically -- received clearance with no additional questions
The Results
90-Day Clearance
Achieved 510(k) clearance in 90 days from our engagement vs. 180-day average. No additional AI requests.
Cost Savings
$125,000 total savings from accelerated timeline, avoided resubmission, and reduced internal resource allocation.
Investor Milestone Met
FDA clearance achieved 30 days before investor deadline, preserving $5M Series C funding milestone.
Market Leadership
Entered market 3 months ahead of primary competitor who was pursuing similar device clearance.
Regulatory Framework Applied
- Clearance Pathway:
- 510(k) -- 21 CFR Part 807 Subpart E
- Device Classification:
- Class II (Special Controls)
- FY2026 510(k) Review Fee:
- $26,067 (standard) / $6,517 (small business)
- Establishment Registration:
- $11,423/year (FY2026 MDUFA)
- Software Guidance:
- Content of Premarket Submissions for Software
- Biocompatibility:
- ISO 10993-1
Important: QMSR Transition (Effective February 2, 2026)
The FDA's Quality Management System Regulation (QMSR) takes effect on February 2, 2026, replacing the current Quality System Regulation (QSR, 21 CFR Part 820). Medical device manufacturers must now comply with the QMSR framework, which incorporates ISO 13485:2016 by reference. If you are pursuing 510(k) clearance in 2026, your quality system documentation should reflect QMSR requirements. In this scenario the company completes its quality system transition ahead of the deadline with Assurentry's guidance.
Timeline Comparison
510(k) Clearance Timeline
Illustrative Cost Comparison
The figures below are illustrative estimates of the costs an avoidable 510(k) delay can create, not a billed result from a specific client.
| Category | Savings |
|---|---|
| 90 days faster market entry (revenue opportunity) | $75,000 |
| Avoided resubmission costs | $25,000 |
| Reduced internal regulatory staff time | $25,000 |
| TOTAL VALUE | $125,000 |
| Assurentry engagement | $35,000 |
| NET ROI | 280% |
AI requests most often stem from gaps in substantial-equivalence rationale, predicate comparison, or testing documentation. A well-organized 510(k) — strong predicate selection, complete test data, and clearly written comparisons — reduces the chance of an AI request and keeps the review moving. FDA still controls the final decision and the review timeline.
Navigating the 510(k) Process?
Whether you're preparing an initial submission or responding to an AI request, our team of device regulatory experts can help you achieve clearance efficiently.